Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

202P - A phase 1b/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) with palbociclib in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer (MBC)

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Arlene Chan

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101223-101223. 10.1016/esmoop/esmoop101223

Authors

A. Chan1, P. Dinh2, D. Day3, M. Slancar4, V. Ganju5, N.J. McCarthy6, J. Lombard7, D. Faltaos8, M. Shilkrut9, R. Wilson8, C. Murphy10

Author affiliations

  • 1 Breast Cancer Research Centre BCRC - WA, Nedlands/AU
  • 2 Crown Princess Mary Cancer Centre Westmead, Westmead/AU
  • 3 Monash Health - Monash Medical Centre, Clayton/AU
  • 4 Icon Cancer Care Southport, Southport/AU
  • 5 Peninsula And South Eastern Haematology and Oncology Group, Frankston/AU
  • 6 ICON Cancer Centre Wesley, Auchenflower/AU
  • 7 Calvary Mater Hospital Newcastle, Newcastle/AU
  • 8 Olema Oncology, San Francisco/US
  • 9 Olema Oncology, 94107 - San Francisco/US
  • 10 Sunshine Hospital - Western Health, St Albans/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 202P

Background

OP-1250 is small molecule CERAN/SERD that binds to and completely blocks transcriptional activity of wild-type and mutant ER. OP-1250 was well tolerated in a phase I/II monotherapy study (OP-1250-001), and the recommended phase II dose is 120 mg once a day (qd). OP-1250 with palbociclib showed synergistic activity in preclinical models. Here we report updates of pharmacokinetics (PK), drug-drug interactions (DDI), safety and efficacy from a study of OP-1250 with palbociclib (OP-1250-002).

Methods

Pts with advanced or MBC with progression on or after ≤1 line of endocrine therapy (prior CDK4/6 inhibitors and chemotherapy were allowed) were enrolled into sequential cohorts to receive escalating doses of OP-1250 PO qd with palbociclib 125 mg PO qd for 21 of 28 days, using a 3+3 design, followed by dose expansion.

Results

As of January 23, 2023, 20 pts have been treated with palbociclib and OP-1250 doses of 30/60/90/120 mg (n=3/3/3/11). Fourteen received prior CDK4/6 inhibitor; 11 received prior palbociclib. No DLTs occurred. The most common (≥4 pts) treatment emergent adverse events (AEs) were neutropenia, nausea, vomiting, anemia, gastroesophageal reflux, constipation, and thrombocytopenia (all were Grade 1-2, except neutropenia). Grade 3 neutropenia occurred in 11 pts (55%). No Grade 4 AEs occurred. The exposure of OP-1250 (n=18) was consistent with the monotherapy study. Palbociclib exposure at steady state was comparable to published monotherapy data when combined with OP-1250 at all dose levels tested. Anti-tumor activity has been observed including partial responses.

Conclusions

OP-1250 did not affect palbociclib PK and no DDIs have been observed with this combination. OP-1250 and palbociclib combination was well tolerated, safety was consistent with individual profiles of each drug as a monotherapy. Tumor responses were observed in this heavily pretreated population. Expanding on our previous report (SABCS 2022), these data provide rationale to continue exploring OP-1250 with the approved dose of palbociclib. Updated data will be presented. (NCT0526610).

Clinical trial identification

NCT0526610.

Legal entity responsible for the study

Olema Oncology.

Funding

Olema Oncology, Pfizer.

Disclosure

D. Faltaos: Financial Interests, Personal, Full or part-time Employment: Olema Oncology; Financial Interests, Personal, Stocks/Shares: Olema Oncology. M. Shilkrut: Financial Interests, Full or part-time Employment: Olema Oncology; Financial Interests, Stocks/Shares: Olema Oncology. R. Wilson: Financial Interests, Personal, Full or part-time Employment: Olema Oncology. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.